SciELO - Scientific Electronic Library Online

 
vol.25 issue1Pheochromocytoma and Paraganglioma: a Challenge beyond the ClinicDNA damage as a potential marker in the clinical follow-up of female patients with treated cancer author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Colombiana de Cancerología

Print version ISSN 0123-9015

Abstract

DE LOS REYES, Amelia et al. Efficacy of Lutetium-177 DOTATATE/TOC in Advanced Neuroendocrine Tumors. rev.colomb.cancerol. [online]. 2021, vol.25, n.1, pp.13-24.  Epub Aug 08, 2021. ISSN 0123-9015.  https://doi.org/10.35509/01239015.132.

Objectives:

The National Cancer Institute first elaborated 177Lu-DOTATATE/TOC in 2009. The purpose of this study was to prove the efficacy of these radiopeptides in the palliative treatment of patients with progressive advanced inoperable neuroendocrine tumors (NETs).

Methods:

A single-phase phase II open clinical trial was conducted in 13 adult patients with grade 1 y 2 NETs, with expression of somatostatin receptors in target lesions proven by Krenning Score 3 or 4 uptake in 99mTc-HYNIC TOC. Patients were treated with 177Lu-DOTATATE or 177Lu-DOTATOC (depending upon availability) at a projected acumulative activitiy of 600-800 mCi divided into 3-4 doses every 6-9 weeks always beginning with a fixed activity of 200 mCi and dosimetry during the first dose. The primary outcome was objective response to therapy.

Results:

13 patients (7 women) aged 63 ± 11.6 years with inoperable advanced NETs were included. The final therapeutic administered activity was 800 mCi, 600 mCi, 400 mCi and 200 mCi in 4, 7, 1 and 1 patients, respectively. The disease control rate at 6 and 12 months was 69.2% and 45.5%, respectively, only obtaining stable disease. Six patients died, 2 of them in the first 6 months. Median overall survival was 15.7 months from the last treatment dose.

Conclusions:

The efficacy of the treatment with 177Lu-DOTATATE or 177Lu-DOTATOC radiopeptides elaborated in-house was confirmed, becoming a management alternative for patients with advanced NETs.

Keywords : Neuroendocrine tumors; Receptors, somatostatin; Lutetium-177; Nuclear Medicine; Radiopharmaceuticals.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )